Form4insider filings, from the source

SEC Form 4 · accession 0001209191-17-047452

AGIOS PHARMACEUTICALS, INC. · AGIO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
David P Schenkein
Officer — Chief Executive Officer · Director
Period of report
Aug 1, 2017
Accepted (ET)
Aug 3, 2017 · 5:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common stockAug 1, 2017M3,000$0.3025A3,000D
Common stockF3Aug 1, 2017S3,000$55.12D0D
Common stockAug 2, 2017M24,000$0.3025A24,000D
Common stockF4Aug 2, 2017S24,000$60.55D0D
Common stockF5holding———272,272ISee footnote
Common stockF6holding———79,082ISee footnote

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock option (right to buy)F7$0.3025Aug 1, 2017M3,000D—Aug 12, 2019Common stock3,000183,656D
Stock option (right to buy)F7$0.3025Aug 2, 2017M24,000D—Aug 12, 2019Common stock24,000159,656D

Explanation of responses